Business ❯ Pharmaceutical Industry ❯ Market Competition

Pricing Strategies

Direct-to-Consumer Sales Generic Drugs Generic Medications Novo Nordisk Consumer Access Eli Lilly Consumer Impact GLP-1 Drugs Subscription Models Copycat Drugs

FDA Approves Langlara as Interchangeable Biosimilar to Lantus

Pharmacy-level substitution could expand access.

Brazil Sets 2026 Medicine Price Caps With Three-Tier Increases Up to 3.81%

India Rolls Out Low-Cost Semaglutide Generics After Patent Expiry

Generics Flood India After Semaglutide Patent Lapses, Slashing Prices Up to 90%

Semaglutide Patent Expires in Brazil, Opening Door to Lower-Cost Rivals

Brazil's Semaglutide Patent Expires Friday, Opening Door to Ozempic Generics

Novo Nordisk to Cut U.S. List Prices for Wegovy, Ozempic and Rybelsus to $675 in 2027

Trump Unveils TrumpRx.gov, a Government Coupon Site for Cheaper Prescriptions

Indiana Sues Eli Lilly, Alleging Scheme to Inflate Insulin Prices

Lilly Cuts Zepbound Cash Prices on LillyDirect as GLP‑1 Price Competition Deepens

Trump's Executive Order Enacts Global Benchmark for U.S. Drug Prices

EU Pushes to Boost Domestic Drug Production Amid Supply Chain Concerns

Taxpayer-Funded Weight-Loss Drugs Face Scrutiny Over High Prices

Novo Nordisk Urges FDA to Ban Compounded Versions of Ozempic and Wegovy